Linezolid

Restricted
Restricted

C. diff Risk

Low

Oral Bioavailability

Excellent

Approximate Cost

Dosing

600mg PO/IV q12h

Must be approved by Infectious Diseases

No dosage adjustment required

Must be approved by Infectious Diseases

General Information

Common Usage

Targeted therapy for infections due to MRSA and VRE.

Drug Monitoring

CBC at least once/week

Visual testing for therapy >3 months or if symptoms develop on therapy.

Adverse Effects

  • Serotonin syndrome

  • Rash

  • Elevated liver enzymes

  • Lactic acidosis

  • Myelosuppression (usually with >2weeks therapy)- reversible

  • Peripheral/optic neuropathy with prolonged courses

Major Interactions

SSRI and other serotonergics/MAOIs - Increased risk of serotonin syndrome. Concurrent usage should be evaluated by prescriber on a case by case basis.

Rifampin decreases linezolid levels.

Pharmacology

Antimicrobial class: Oxazolidinone

Pregnancy category: C

Average serum half life: 5 hours

Urine penetration: Therapeutic

Lung penetration: Therapeutic

CSF penetration: Therapeutic